Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Hypertension Reports
Erschienen in: Current Hypertension Reports 9/2017

01.09.2017 | Hypertension and the Kidney (RM Carey, Section Editor)

Hyperuricemia, Type 2 Diabetes Mellitus, and Hypertension: an Emerging Association

verfasst von: Ibrahim Mortada

Erschienen in: Current Hypertension Reports | Ausgabe 9/2017

Einloggen, um Zugang zu erhalten

Abstract

Uric acid is the final oxidation product of purine metabolism in circulation and has been associated with the occurrence of gout and kidney stones. Type 2 diabetes mellitus and hypertension are two important public health challenges, and both are linked to increased risk of cardiovascular events. Hyperuricemia has recently emerged as an independent risk factor in the development of type 2 diabetes mellitus and hypertension through several proposed mechanisms. Few clinical trials investigated the use of uric acid lowering agents in the management of these two disease entities; however, their results provided encouraging evidence to a potential role for these agents in fighting disease burden. Larger randomized controlled trials are therefore warranted to establish the role of uric acid as a promising target for novel therapeutic interventions in the management of type 2 diabetes mellitus and hypertension.
Literatur
1.
Rock KL, Kataoka H, Lai J-J. Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol. 2013;9(1):13–23.CrossRefPubMed
2.
3.
Aung T, Myung G, FitzGerald JD. Treatment approaches and adherence to urate-lowering therapy for patients with gout. Patient Prefer Adherence. 2017;11:795–800.CrossRefPubMedPubMedCentral
4.
5.
6.
Pradeepa R, Mohan V. Prevalence of type 2 diabetes and its complications in India and economic costs to the nation. Eur J Clin Nutr. 2017;71(7):816–24.CrossRefPubMed
7.
Wang C, et al. Quercetin and allopurinol ameliorate kidney injury in STZ-treated rats with regulation of renal NLRP3 inflammasome activation and lipid accumulation. PLoS One. 2012;7(6):e38285.CrossRefPubMedPubMedCentral
8.
Rock KL, Kataoka H, Lai JJ. Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol. 2013;9(1):13–23.CrossRefPubMed
9.
• Jalal DI, et al. Uric acid as a target of therapy in CKD. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2013;61(1):134–46. A review focusing on uric acid as a potential therapeutic target to prevent kidney disease onset and progression. CrossRef
10.
Maiuolo J, et al. Regulation of uric acid metabolism and excretion. Int J Cardiol. 2016;213:8–14.CrossRefPubMed
11.
12.
13.
14.
15.
Mende C. Management of chronic kidney disease: the relationship between serum uric acid and development of nephropathy. Adv Ther. 2015;32:1177–91.CrossRefPubMedPubMedCentral
16.
Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol. 2010;6(1):30–8.CrossRefPubMed
17.
•• Li L, et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: a systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 2014;15:122. This systematic review and meta-analysis shows that elevated serum uric acid levels showed an increased risk for the development of chronic renal dysfunction. CrossRefPubMedPubMedCentral
18.
Lapi F, et al. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ : British Medical Journal. 2013;346:e8525.CrossRefPubMedPubMedCentral
19.
Zhu J-N, et al. Dietary factors associated with hyperuricemia and glycolipid metabolism disorder in middle-aged and elderly people. Sichuan da xue xue bao Yi xue ban = Journal of Sichuan University Medical science edition. 2016;47(1):68–72.PubMed
20.
Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63(10):3136–41.CrossRefPubMed
21.
Anton FM, et al. Sex differences in uric acid metabolism in adults: evidence for a lack of influence of estradiol-17 beta (E2) on the renal handling of urate. Metabolism. 1986;35(4):343–8.CrossRefPubMed
22.
Hak AE, Choi HK. Menopause, postmenopausal hormone use and serum uric acid levels in US women—the Third National Health and Nutrition Examination Survey. Arthritis Res Ther. 2008;10(5):R116.CrossRefPubMedPubMedCentral
23.
•• Lv Q, et al. High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. PLoS One. 2013;8(2):e56864. This meta-analysis of prospective cohort studies provides strong evidence that high level of serum uric acid is independent of other established risk factors, for developing type 2 diabetes in middle-aged and older people. CrossRefPubMedPubMedCentral
24.
Jia Z, et al. Serum uric acid levels and incidence of impaired fasting glucose and type 2 diabetes mellitus: a meta-analysis of cohort studies. Diabetes Res Clin Pract. 2013;101(1):88–96.CrossRefPubMed
25.
Kim SC, Liu J, Solomon DH. Risk of incident diabetes in patients with gout: a cohort study. Arthritis & rheumatology (Hoboken, NJ). 2015;67(1):273–80.CrossRef
26.
Liu Y, et al. Serum uric acid levels and the risk of impaired fasting glucose: a prospective study in adults of north China. PLoS One. 2013;8(12):e84712.CrossRefPubMedPubMedCentral
27.
Lee S-H, Kim K-M, Kim K-N. Combined effect of serum gamma-glutamyltransferase and uric acid on incidence of diabetes mellitus: a longitudinal study. Medicine. 2017;96(19):e6901.CrossRefPubMedPubMedCentral
28.
Krishnan E, et al. Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout. QJM: An International Journal of Medicine. 2013;106(8):721–9.CrossRef
29.
Maahs DM, et al. Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study. Curr Diab Rep. 2013;13(4):550–9.CrossRefPubMedPubMedCentral
30.
31.
Matsuoka T, et al. Glycation-dependent, reactive oxygen species-mediated suppression of the insulin gene promoter activity in HIT cells. J Clin Investig. 1997;99(1):144–50.CrossRefPubMedPubMedCentral
32.
Liu P, et al. The effects of allopurinol on the carotid intima-media thickness in patients with type 2 diabetes and asymptomatic hyperuricemia: a three-year randomized parallel-controlled study. Intern Med. 2015;54(17):2129–37.CrossRefPubMed
33.
Takir M, et al. Lowering uric acid with allopurinol improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia. J Investig Med. 2015;63(8):924–9.CrossRefPubMed
34.
El-Bassossy HM, et al. Ameliorative effect of allopurinol on vascular complications of insulin resistance. Journal of Diabetes Research. 2015;2015:10.CrossRef
35.
•• Grayson PC, et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;63(1):102–10. This systematic review and meta-analysis show that hyperuricemia is associated with an increased risk for incident hypertension, independent of traditional hypertension risk factors. CrossRef
36.
Komendarek-Kowalska M. The assessment of renal function in patients with newly diagnosed hypertension—the role of hyperuricemia as a risk factor for chronic kidney disease—preliminary study. Pol Merkur Lekarski. 2017;42(251):193–6.PubMed
37.
Perlstein TS, et al. Uric acid and the development of hypertension: the normative aging study. Hypertension. 2006;48(6):1031–6.CrossRefPubMed
38.
Cicero AF, et al. Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis: data from the Brisighella Heart Study. J Hypertens. 2014;32(1):57–64.CrossRefPubMed
39.
• Mazzali M, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101–6. The study reveals that elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. CrossRefPubMed
40.
Yu MA, et al. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens. 2010;28(6):1234–42.PubMed
41.
•• Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300(8):924–32. This randomized trial shows that treatment with allopurinol reduces blood pressure in adolescents with newly diagnosed hypertension. CrossRefPubMedPubMedCentral
42.
Soletsky B, Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension. 2012;60(5):1148–56.CrossRefPubMed
43.
•• Kanbay M, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007;39(4):1227–33. This study brings indirect evidence that management of hyperuricemia may prevent the progression of renal disease, even in patients with normal renal function. CrossRefPubMed
Metadaten
Titel
Hyperuricemia, Type 2 Diabetes Mellitus, and Hypertension: an Emerging Association
verfasst von
Ibrahim Mortada
Publikationsdatum
01.09.2017
Verlag
Springer US
Erschienen in
Current Hypertension Reports / Ausgabe 9/2017
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-017-0770-x

Weitere Artikel der Ausgabe 9/2017

Current Hypertension Reports 9/2017 Zur Ausgabe

Hypertension and Obesity (E Reisin, Section Editor)

Regression of Left Ventricular Mass After Bariatric Surgery

Blood Pressure Monitoring and Management (J Cockcroft, Section Editor)

Relevance of Haemodynamics in Treating Pre-eclampsia

Letter to the Editor

Comments on: Lyubarova, R. and Gosmanova, E.O. Mineralocorticoid Receptor Blockade in End-Stage Renal Disease. Current Hypertension Reports, 2017. 19(5)

Antihypertensive Agents: Mechanisms of Drug Action (ME Ernst, Section Editor)

Herbs Used for the Treatment of Hypertension and their Mechanism of Action

Hypertension and the Kidney (RM Carey, Section Editor)

Effects of RAAS Inhibitors in Patients with Kidney Disease

Blood Pressure Monitoring and Management (J Cockcroft, Section Editor)

Pulse Waveform Analysis: Is It Ready for Prime Time?

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise